Subsequently an Eichrom method was used to extract the Actinium. Purified Ac225 was isolated and labeled to an anti-epithereal growth factor (EFGR) antibody. Ac225-DOTA-nimotuzumab is an effective alpha therapy agent against EFGR+ cancers
As of now, the regular milking of the U-Th-Ac generator has yielded MBq quantities of Ac225. Improvements, including an automated system, are under way.
The resulting Ac225 was used to label DOTA- nimotuzumab with radiochemical yield of 25% and purity 95% and a specific activity of 0.03 MBq/microgram.
Presented By: Patrick Causy from Canadian Nuclear Laboratory, Chalk River, Canada
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.